Fig. 2: Progression-free survival, overall survival, and duration of response of real-world patients treated with teclistamab.
A Progression-free survival (PFS). B Overall survival (OS). C Duration of response (DoR).
Fig. 2: Progression-free survival, overall survival, and duration of response of real-world patients treated with teclistamab. | Blood Cancer Journal
